Targeting the pathobiology of neutrophil extracellular traps
Citryll – a dutch biotech company – is taking a new approach to treat autoimmune and other human inflammatory diseases like lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis and organ damage due to sepsis, by targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation or acquired immunity.
Scientific Approach
Citryll targets Neutrophil Extracellular Traps (NET) formation with a human antibody CIT-013 that interferes with the formation of NETs as well as promotes the clearance of NETs. A range of human diseases with potential for SLE, RA, vasculitis, asthma, IPF and other indications can be treated with CIT-013.
CIT-013 Development
A first human study started in the summer of 2021 starting with a Single Ascending Dose (SAD) study in healthy volunteers. GMP production and formulation of the antibody drug product was carried out by Citryll’s CMC partner Lonza and CTA enabling studies were finalised in Spring 2021.